Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Fleischhacker, WW; Hinterhuber, H; Bauer, H; Pflug, B; Berner, P; Simhandl, C; Wolf, R; Gerlach, W; Jaklitsch, H; Sastre-y-Hernández, M.
A multicenter double-blind study of three different doses of the new cAMP-phosphodiesterase inhibitor rolipram in patients with major depressive disorder.
Neuropsychobiology. 1992; 26(1-2):59-64
Doi: 10.1159/000118897
Web of Science
PubMed
FullText
FullText_MUG
- Autor*innen der Med Uni Graz:
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- A multicenter randomized 4-week interindividual double-blind study was carried out in 58 hospitalized patients with major depressive disorder (DSM III 296.23, 296.22, 296.33, 296.32, 296.53 and 296.52) to test the dose-effect relationship of three different doses of the new cAMP-phosphodiesterase inhibitor rolipram: 3 x 0.25 mg, 3 x 0.50 mg and 3 x 1.00 mg rolipram/day. With respect to the desired effect, the 3 x 0.50 mg dosage stood out from the others in almost all relevant parameters. With respect to the response rate, the efficacy of the 3 x 0.25 mg dosage was about the same as that reported in the literature for placebo. The inferior performance of the 3 x 1.00 mg dosage compared to the 3 x 0.50 mg dosage might indicate a reverse U-shaped dose-effect relationship. There was good tolerance to all three dosages. There were no findings that might cast doubt on the safety of the dosages tested.
- Find related publications in this database (using NLM MeSH Indexing)
- Antidepressive Agents - administration and dosage
- Depressive Disorder - drug therapy
- Dose-Response Relationship, Drug - drug therapy
- Double-Blind Method - drug therapy
- Humans - drug therapy
- Phosphodiesterase Inhibitors - administration and dosage
- Psychiatric Status Rating Scales - administration and dosage
- Pyrrolidinones - administration and dosage
- Rolipram - administration and dosage
- Find related publications in this database (Keywords)
- Rolipram
- Major Depressive Disorder
- Phosphodiesterase Inhibitor
- Antidepressant